Tiny genetic variation can predict ovarian cancer outcome

	Tweet

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

The findings, published in the journal Oncogene, provide new insights into the biology of a new class of cancer marker and suggest a genetic test may help guide the treatment of women with ovarian cancer.

“This gives us a way to identify which women are at highest risk for resistance to platinum chemotherapy, the standard treatment for ovarian cancer, and helps identify ovarian cancer patients with the worst outcomes,” said Joanne Weidhaas, associate professor of therapeutic radiology and senior author of the study. “There just aren’t many inherited gene variants than can do that.”

Women who possess the biomarker identified by the Yale team – a variant of the well-known KRAS oncogene – are three times more resistant to standard platinum chemotherapy than women without the variant. Also, post-menopausal women with the variant are significantly more likely to die from ovarian cancer. About 12-15 percent of Caucasians and 6 percent of African-Americans are born with the variant of the gene, which helps regulate destruction of damaged cells. This variant is found in up to 25% of newly diagnosed ovarian cancer patients.

Although good alternatives to chemotherapy are not yet available for women with ovarian cancer and this variant, several drugs in development which target the KRAS gene and associated pathways have shown great promise, Weidhaas said.

Weidhaas is a co-founder of a company that has licensed intellectual property from Yale that has developed a diagnostic test based on the Kras-variant.

The biomarker intrigues scientists because it is a functional variant in an area of DNA that does not code for proteins. Instead this variant disrupts how a microRNA controls gene expression.

“This is a new paradigm,” Weidhaas said.

Yale researchers have also found this microRNA variant of the KRAS gene is associated with an increased risk of developing breast cancer and lung cancer. Other researchers have found associations with poor outcome in colon as well as head and neck cancers.

In laboratory tests, researchers blocked the variant and significantly reduced growth of ovarian cancer cells. This suggests targeting the variant site may someday help treat cancer in these patients.

###

The study was funded by the NIH, the National Cancer Institute and the Merkel Foundation.

Other Yale authors are Elena S. Ratner, Florence K. Keane, Michelle Glasgow, Sunitha Nallur, Yanhong Deng, Stefania Bellone, Marta Boeke, Xiaopan Yao, Daniel Zelterman, Herbert Yu, Thomas J. Rutherford, Peter E. Schwartz, Frank J. Slack and Alessandro D. Santin.

###

Bill Hathaway

203-432-1322
Yale University

RELATED STORIES:
Processed meat linked to higher ovarian cancer risk   An experiment in earlier detection of ovarian cancer   Ovarian Cancer Study Gets Aid   Women with Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years   DNA Repair Genes May Predict Ovarian Cancer Survival   Study Explains High Platelets in Ovarian Cancer Patients; Survival Reduced   Motor protein may offer promise in ovarian cancer treatment   Virus kills ovarian cancer cells   Birth after cancer treatment with removal and storage of ovary   Possible New Therapy for Patients with Platinum-Resistant Ovarian Cancer   2 reproductive factors are important predictors of death from ovarian cancer   Nanotech gene therapy kills ovarian cancer in mice   Body cavity drugs cut ovarian cancer death risk   Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers   Ovarian cancer survival influenced by MD specialty   Ovarian cancer screening popular despite guidelines   Late-Stage Ovarian Cancer Therapy Shows Promise in Phase I Trial   TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer   65% of ovarian cancer cells sideline body’s defences   Dietary factors influence ovarian cancer survival rates   Cancer-Reducing Benefits of Preventive Surgery May Be Specific to Gene Mutation   Specialists provide best outcome for ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]